Antibiotics Market Share, Antibiotics Market Size, Antibiotics Market Product Type, Antibiotics Market Growth.

Antibiotics Market Forecast to 2028 - Covid-19 Impact and Global Analysis by Drug Class (Sulfonamides, Aminoglycosides, Carbapenem, Macrolides, Fluoroquinolones, Penicillin, Cephalosporin, Others); Action Mechanism (Mycolic Acid Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors), and Geography.

The Antibiotics was valued at US$ 44,111.31 million in 2020 and is projected to reach US$ 59,253.24 million by 2028; it is expected to grow at a CAGR of 4.0% from 2021 to 2028.

 

Market Overview: The Cephalosporin Segment by Drug Class Is Expected to Dominate the Market Over the Forecast Period

According to the latest study on ‘Antibiotics Market Forecast to 2028 - Covid-19 Impact and Global Analysis by Drug Class and Action Mechanism.’ The global antibiotics market was valued at US$  44,111.31 million in 2020 and is projected to reach US$  59,253.24 million in 2028; it is expected to grow at a CAGR of 4.0% during 2021–2028. The report provides trends prevailing in the global antibiotics  market and the factors driving market along with those that act as hindrances.

Based on n drug class, the antibiotics market is segmented into Cephalosporin, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The cephalosporin segment held the largest share of the market in 2020; however the fluoroquinolones segment is anticipated to register the highest CAGR of 5.3% in the market during the forecast period. Additionally, increasing incidence of pneumonia, bloodstream infections, and Urinary Tract Infections (UTI) is expected to increase the demand for carbapenems class of antibiotics in coming years. Moreover, the lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to develop geographical footprint in lower and middle-income countries.

The growth of the market is attributed to some of the key factors, such as rising prevalence of bacterial infections and increasing development of generic drugs. However, challenges associated with tedious  and expensive process of antibiotic development and due to coronavirus pandemic are expected to restraint the growth of the market during the forecast years.

Pfizer, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Abbott, GlaxoSmithKine Plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, and Astellas Pharma are among the leading companies operating in the antibiotics market. The companies are focused towards the adoption of organic strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2017, Pfizer's launched new antibiotic for multidrug resistant (MDR) infections Zavicefta in the UK and Germany, its first lauch was in EU markets.

Get Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00003406/

Buy Now: https://www.theinsightpartners.com/buy/TIPRE00003406/

 

The report segments global antibiotics market as follows:

The growing prevalence of bacterial infection is one of the major factors increasing the demand for antibiotics globally. However, expensive process of antibiotic development is likely to pose a negative impact on the market growth, which in turn will restrain the growth of the market during the forecast years.

Bacteria are microscopic and single-cell omnipresent organisms. Bacterial infection refers to the proliferation of harmful bacterial strains on or inside the human body. These microorganisms can infect any area of the body and may lead to severe consequences. A few of the indications of bacterial infections include pneumonia, meningitis, and food poisoning. Several commonly occurring pediatric bacterial infections are acute otitis media (AOM), sinusitis, bronchitis, upper respiratory tract infection, and pharyngitis.

The prevalence of infectious disease caused by bacteria is increasing day by day worldwide. According to a study published by the American Society for Microbiology (ASM) in 2019, 1.5–4.5 million infections across the world are caused by the Carbapenem-resistant bacterial strains belonging to the Enterobacteriaceae group every year. Additionally, the same risk factor leads to ~49,000 hospitalization cases in the US every year. Moreover, according to a study published by UNICEF, in 2018, pneumonia was the cause for ~1,755,000 deaths among children below the age of five; moreover, ~1,200,000 children lost their lives by diarrhea around the globe. Further, according to a study published by the NCBI in 2018, campylobacterial infection, which is transmitted through the consumption of poultry, is one of the leading causes of bacterial foodborne infections in developed countries, which is causing a major economic burden. According to estimates given by the World Health Organization (WHO) in 2018, every year, ~33 million people die of campylobacteriosis worldwide. Such potential increase in prevalence of bacterial infections is expected to continue to drive the growth of antibiotics market during the forecast period. Thus, the increasing prevalence of such drug-resistant bacteria compels the manufacturers and R&D faculties to come up with new variants of antimicrobials effective against the new, as well as old, bacterial strains, thereby fueling the growth of the antibiotics market.

The global antibiotics market is segmented into drug class and action mechanism. Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others. The cephalosporin segment held the largest share of the market in 2020; whereas the fluoroquinolones segment is anticipated to register the highest CAGR in the market during the forecast period.  Based on action mechanism, the antibiotics market is segmented into mycolic acid inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, protein synthesis inhibitors, and cell wall synthesis inhibitors. The cell wall synthesis inhibitors segment held the largest share of the market in 2020; whereas the DNA synthesis inhibitors segment is estimated to register the highest CAGR in the market during the forecast period.

A few of the essential primary and secondary sources referred  during the preparation of the report are, Food and Drug Administration, World Health Organization (WHO), Organization for Economic Co-operation and Development, and National Cancer Foundations

 

  • By Drug Class
  • Cephalosporin
  • Penicillin
  • Fluoroquinolones
  • Macrolides
  • Carbapenem
  • Aminoglycosides
  • Sulfonamides
  • Others
  • By Action Mechanism
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East and Africa (MEA)
    • Saudi Arabia
    • UAE
    • South Africa
  • South & Central America (SCAM)
    • Brazil
    • Argentina

About The Insight Partners

The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Healthcare, Media, and Telecommunication.

Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, products, applications, end users etc., which helps our clients to gain a deeper analytical understanding of various research topics.

 

Contact Us

If you have any queries about this report or would like further information, please 

Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the publisher, “The Insight Partners”.

The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions, and recommendations that “The Insight Partners” delivers will be based on information gathered in good faith from primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such, “The Insight Partners” can accept no liability whatsoever for actions taken based on any information that may subsequently prove to be incorrect.